CMPX: רווח נקי למניה (EPS TTM) Compass Bio
High demand for targeted immunotherapy is driving the expansion of Compass Therapeutics, and the chart of net profit per share for the last 12 months is available for analysis on GURU.Markets, where the -0.40 mark reflects the latest data. Funding is based on investments and partnerships for antibody development. The absence of debt and the success of the CTX-009 drug make Compass Therapeutics (CMPX) an attractive acquisition target for Big Pharma.
פילוחי נתונים אנליטיים מרוכזים עבור Compass Therapeutics Inc (CMPX)
High barriers to entry in the cancer immunotherapy segment due to expensive R&D make the analysis of Compass Therapeutics (CMPX) actual earnings critically important. By examining the rolling annual EPS chart, an investor can see the net profit per share over 12 months, which allows them to filter out market noise and determine the fair value of the business relative to its actual earnings.
